Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital led a $200m Series C round in NiKang Therapeutics.

Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital led a $200m Series C round in NiKang Therapeutics, a clinical stage biotech company focused on developing innovative small molecule oncology medicines, with participation from EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, BlackRock, RA Capital Management, Surveyor Capital, Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors, Logos Capital, CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital. "We are thrilled to have such an outstanding group of investors as our shareholders. Their support of our vision allows us to build the world’s leading precision oncology company. We are now well positioned to rapidly advance our pipeline into clinic including our differentiated HIF-2 alpha inhibitor, and to bring our company to the next level of growth," Zhenhai Gao, NiKang President and CEO.